Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31618186 | 0.90 | SIGMAR1 (0.39) | PIN1SIGMAR1L3MBTL1KMT2ATDP1 | |
| SCHEMBL27367115 | 0.83 | HCRTR1 (0.41) | PIN1SIGMAR1KMT2ATDP1PTGDR2 | |
| SCHEMBL27367147 | 0.81 | SIGMAR1 (0.48) | SIGMAR1KMT2APTGDR2MTNR1AMTNR1B | |
| SCHEMBL5235807 | 0.79 | TDP1 (0.45) | PIN1L3MBTL1KMT2ATDP1PTGDR2 | |
| SCHEMBL24821196 | 0.77 | TDP1 (0.64) | PIN1KMT2ATDP1PTGDR2MTNR1A | |
| SCHEMBL27367110 | 0.76 | HPGD (0.56) | L3MBTL1KMT2ATDP1MEN1LMNA | |
| SCHEMBL31618222 | 0.75 | SIGMAR1 (0.42) | PIN1SIGMAR1L3MBTL1KMT2ATDP1 | |
| SCHEMBL31618139 | 0.75 | SIGMAR1 (0.42) | PIN1SIGMAR1L3MBTL1KMT2ATDP1 | |
| SCHEMBL27366186 | 0.74 | HTR2A (0.52) | MTNR1AMTNR1BNQO2 | |
| Fumaric Acid SCHEMBL31331788 | 0.73 | HTR2A (0.46) | KMT2AMTNR1AMTNR1BMEN1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-10-30 | — | — | US | disclosed |
| EP-4532462-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384406-A | Compounds of formula (I) | 赛洛私人有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | SDHA, PYGB, SLC18A2 | PIN1 745/4885SIGMAR1 623/4885L3MBTL1 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.